`

Ryvu Therapeutics

Biotechnology

Specialities :
Oncology
Drug discovery
Biotech
Kinase inhibitor
Cancer metabolism

+4

revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$8.72M
size-icon Size
201 - 500

Frequently Asked Questions About Ryvu Therapeutics

What does Ryvu therapeutics do?+

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvus most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced...

What are Ryvu therapeutics's specialties? +

Oncology,drug discovery,biotech,kinase inhibitor,cancer metabolism,immuno-oncology,aml,hr-mds,and synthetic lethality

What is Ryvu therapeutics's industry? +

Ryvu therapeutics operates in the Biotechnology industry.

What is Ryvu therapeutics's revenue? +

Ryvu therapeutics's revenue is 11m - 100m

What is Ryvu therapeutics's company size? +

Ryvu therapeutics has 201 - 500 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.